Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEQUA vs CELLCEPT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunosuppressant; binds to cyclophilin D in mitochondria, inhibiting opening of mitochondrial permeability transition pore (m PTP), which reduces T-lymphocyte activation and cytokine release. Also forms complex with cyclophilin A to inhibit calcineurin, suppressing IL-2 production and T-cell proliferation.
Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.
Dry eye disease due to keratoconjunctivitis sicca (KCS),Post-keratoplasty dry eye,Dry eye in Sjögren's syndrome
Prophylaxis of organ rejection in renal transplant recipients,Prophylaxis of organ rejection in cardiac transplant recipients,Prophylaxis of organ rejection in hepatic transplant recipients,Off-label: Treatment of lupus nephritis, autoimmune diseases, and other transplant indications
Instill one drop of 0.09% ophthalmic solution in each eye twice daily, approximately 12 hours apart.
Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.
Terminal elimination half-life is approximately 8.4 hours (range 6-10 hours) in healthy adults; prolonged in hepatic impairment and pediatric patients.
Terminal elimination half-life of MPA is approximately 17.9 ± 6.5 hours in renal transplant patients. Clinical significance: dosing interval of 12 hours maintains therapeutic levels.
Hepatic via CYP3A4 and CYP3A5; also undergoes fecal elimination with enterohepatic recirculation.
Mycophenolate mofetil is hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is primarily metabolized by glucuronidation via UDP-glucuronosyltransferases (UGT1A9 and UGT2B7) to MPA-glucuronide (MPAG), which is excreted in urine.
Primarily fecal (90%) with minor renal excretion (<1% unchanged drug). Biliary excretion is the major route for elimination of cyclosporine metabolites.
Mycophenolic acid (MPA) is primarily excreted in urine as mycophenolic acid glucuronide (MPAG) (87% of dose); <1% excreted as unchanged MPA. Fecal excretion accounts for approximately 6% of dose.
90-98% bound primarily to lipoproteins (HDL, LDL) and to a lesser extent albumin and globulins.
97% bound to albumin. In renal impairment or hypoalbuminemia, free fraction increases.
4-8 L/kg, indicating extensive distribution into tissues (e.g., fat, liver, kidneys).
Apparent volume of distribution of MPA is approximately 3.6 L/kg (range 1.5-5.0 L/kg), indicating extensive tissue distribution.
Ophthalmic emulsion: systemic bioavailability is negligible (<0.1%) due to low absorption from the eye.
Oral bioavailability of mycophenolate mofetil is approximately 94% (converted to MPA). Intravenous: 100%.
No dosage adjustment required for renal impairment.
For GFR 10-50 m L/min: maximum 2 g daily; for GFR <10 m L/min: maximum 1 g daily.
No dosage adjustment required for hepatic impairment.
No dosage adjustment required for hepatic impairment. No Child-Pugh based modifications are established.
Safety and efficacy in pediatric patients have not been established.
For ages 3 months to 18 years: 600 mg/m2 orally twice daily; maximum 2 g daily. Intravenous: same oral dose converted to IV.
No specific dosage adjustment recommended; use with caution due to potential for increased systemic exposure.
No specific dose adjustment, but start at lower end of dosing range due to age-related renal impairment. Monitor for adverse effects.
Increased risk of infection and lymphoproliferative disorders including post-transplant lymphoproliferative disorder (PTLD).
Increased risk of pregnancy loss and congenital malformations; must avoid pregnancy during therapy. Use in women of childbearing potential only if contraception is used and pregnancy is excluded.
Increased susceptibility to infections,Potential for lymphoproliferative disorders and other malignancies,May cause renal impairment, hypertension, hyperkalemia, and hyperuricemia,Monitor blood cyclosporine levels to avoid toxicity,Avoid concurrent use of live vaccines,Caution with other nephrotoxic drugs
Increased susceptibility to infections (e.g., CMV, BK virus), lymphomas, and other malignancies; dose reduction in renal impairment; avoid use with azathioprine; monitor for neutropenia, GI bleeding, and progressive multifocal leukoencephalopathy.
Hypersensitivity to cyclosporine or any component,Uncontrolled hypertension,Severe renal impairment (except in transplant setting),Active infections,Concurrent use with PUVA or UVB therapy
Hypersensitivity to mycophenolate mofetil or mycophenolic acid; women who are pregnant or planning pregnancy (unless no alternative); women of childbearing potential not using effective contraception.
No significant food interactions reported for ophthalmic cyclosporine. However, patients should avoid touching the dropper tip to food surfaces. No dietary restrictions are necessary.
Avoid taking with food high in fat or protein as it may reduce absorption. Grapefruit juice may decrease mycophenolate absorption; avoid concurrent consumption. No specific dietary restrictions besides maintaining consistent intake with meals.
CEQUA (cyclosporine ophthalmic solution) is classified as Pregnancy Category C. Animal studies have shown embryotoxic and fetotoxic effects at doses 0.2-0.8 times the human ocular dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: limited data, theoretical risk of immunosuppression. Second and third trimesters: no specific human data, but systemic cyclosporine is associated with increased risk of prematurity and low birth weight.
First trimester exposure is associated with a high risk of congenital malformations, including craniofacial defects (cleft lip/palate), cardiovascular anomalies, and neural tube defects. Second and third trimester exposure may cause intrauterine growth restriction, preterm delivery, and neonatal immunosuppression. Mycophenolic acid is contraindicated in pregnancy unless no alternative treatment is available.
Systemic cyclosporine is excreted in human milk. The M/P ratio is approximately 0.3-0.6. However, CEQUA is an ophthalmic formulation with minimal systemic absorption. Unknown whether topically applied cyclosporine is excreted in milk. Use caution, considering the importance of the drug to the mother. Breastfeeding infants should be monitored for potential adverse effects such as immune suppression.
M/P ratio is unknown. Mycophenolic acid is excreted into breast milk in small amounts; however, due to potential for serious adverse effects in the nursing infant, including immunosuppression and growth delay, breastfeeding is not recommended during therapy.
No specific dosing adjustments are recommended for CEQUA in pregnancy due to its local administration and minimal systemic absorption. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered protein binding) are unlikely to affect ophthalmic drug levels. No dose adjustment required.
No specific dose adjustments are established due to lack of pharmacokinetic data in pregnancy. Systemic exposure may be reduced due to increased plasma volume and metabolism; however, due to teratogenicity, use is contraindicated. If unavoidable, consider monitoring mycophenolic acid trough levels and adjust dose to maintain therapeutic range (1.0–3.5 mg/L), but safety is not established.
CEQUA (cyclosporine ophthalmic solution 0.09%) is a calcineurin inhibitor immunosuppressant indicated for keratoconjunctivitis sicca (dry eye disease). It increases tear production by inhibiting T-cell activation. Important: CEQUA requires no refrigeration (unlike Restasis), and the vehicle contains no preservatives. Use with caution in patients with active ocular infections; do not administer while wearing contact lenses. Onset of effect may take 2-4 weeks; maximum benefit may require 6 months. Contraindicated in patients with known hypersensitivity to cyclosporine.
Mycophenolate mofetil (CELLCEPT) is a prodrug of mycophenolic acid, an inosine monophosphate dehydrogenase inhibitor. It is used for prophylaxis of organ rejection in renal, cardiac, and hepatic transplant recipients. Monitor for leukopenia, neutropenia, and infections. Dose adjustment required in renal impairment (GFR <25 m L/min). Avoid use in pregnancy (Pregnancy Category D). Contraindicated in hypersensitivity to mycophenolate. Intravenous administration should be over 2 hours. Monitor for GI bleeding and CMV infection.
CEQUA is a prescription eye drop used to increase tear production in dry eye disease.,Instill one drop in each eye twice daily, about 12 hours apart.,Remove contact lenses before use; wait at least 15 minutes before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,CEQUA comes in a single-use vial; use immediately after opening and discard any remaining solution.,Temporary blurred vision may occur after instillation; wait until vision clears before driving.,Report any eye pain, vision changes, or signs of infection (redness, discharge) to your doctor.,Store CEQUA at room temperature (20-25°C); do not refrigerate or freeze.,It may take several weeks to notice improvement; continue use as prescribed even if you feel no effect initially.
Take exactly as prescribed, with or without food. Do not crush or chew capsules.,Avoid sunlight and use sunscreen due to increased risk of skin cancer.,Report any signs of infection (fever, sore throat, unusual bleeding or bruising).,Use effective contraception during treatment and for 6 weeks after stopping if female of childbearing potential.,Do not breastfeed while taking this medication.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEQUA vs CELLCEPT, answered by our medical review team.
CEQUA is a Immunosuppressant that works by Immunosuppressant; binds to cyclophilin D in mitochondria, inhibiting opening of mitochondrial permeability transition pore (m PTP), which reduces T-lymphocyte activation and cytokine release. Also forms complex with cyclophilin A to inhibit calcineurin, suppressing IL-2 production and T-cell proliferation.. CELLCEPT is a Immunosuppressant that works by Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEQUA and CELLCEPT depend on the specific clinical indication. These are both Immunosuppressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEQUA is: Instill one drop of 0.09% ophthalmic solution in each eye twice daily, approximately 12 hours apart.. The standard adult dose of CELLCEPT is: Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEQUA and CELLCEPT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEQUA is classified as Category C. CEQUA (cyclosporine ophthalmic solution) is classified as Pregnancy Category C. Animal studies have shown embryotoxic and fetotoxic effects at doses 0.2-0.8 times the human ocular . CELLCEPT is classified as Category C. First trimester exposure is associated with a high risk of congenital malformations, including craniofacial defects (cleft lip/palate), cardiovascular anomalies, and neural tube de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.